Daewoong Bio Signs Co-Promotion Deal with Youngjin Pharm for Pulmecool and Linezolin
"Expanding Portfolio in Respiratory and Anti-Infective Treatments"
Daewoong Bio announced on July 2 that it has signed a co-promotion agreement with Youngjin Pharm for two prescription drugs, expanding its portfolio into the respiratory and anti-infective treatment sectors.
Under this agreement, starting this month, Daewoong Bio will jointly promote Youngjin Pharm's "Pulmecool Nebulizer Suspension" (active ingredient: budesonide) and "Linezolin" (active ingredient: linezolid). Youngjin Pharm will ensure a stable supply of the two products based on its product development and supply capabilities, while Daewoong Bio will focus on establishing the products in the market by leveraging its prescription drug sales and marketing expertise.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Daewoong Bio stated, "We plan to strengthen our corporate competitiveness by expanding our product portfolio from a focus on central nervous system (CNS) drugs to include respiratory and anti-infective areas."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.